Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Liquidia Corporation (LQDA) vs Dr. Reddy's Laboratories Ltd (RDY)

Liquidia Corporation and Dr. Reddy's Laboratories Ltd are both Drug Manufacturers Specialty & Generic companies. Dr. Reddy's Laboratories Ltd is the larger, with a market value of $10.0B against $6.4B — 1.6× the size. Dr. Reddy's Laboratories Ltd trades at the lower P/E: 30.8× against 43.6×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against −11.6%. Liquidia Corporation has the higher net margin (30.7% vs 9.81%) and the higher return on invested capital (121.1% vs 5.89%). Across the 22 metrics below, Liquidia Corporation leads on 13 and Dr. Reddy's Laboratories Ltd on 9.

Valuation

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
P/E 43.59 30.85 20.14
P/S 13.49 2.79 2.25
P/B 31.17 2.35 1.90
Price to free cash flow 40.36 69.03 16.54
EV/EBITDA 35.09 15.92 12.29
EV/Sales 13.25 2.76 2.56
Earnings yield 2.29% 3.24% (2.99%)
Free cash flow yield 2.48% 1.45% 0.00%

Profitability

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
Gross margin 92.54% 50.00% 53.94%
Operating margin 37.39% 10.91% 0.00%
Net margin 30.74% 9.81% 0.00%
Free cash flow margin 33.42% 4.05% 0.00%
Return on equity 131.82% 8.21% (0.40%)
Return on assets 35.57% 5.55% (3.32%)
Return on invested capital 121.05% 5.89% 0.00%

Growth

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 2,233.65% (11.60%) 10.01%
EPS growth (last fiscal year) 51.81% (30.38%) —
Revenue growth, 5-year CAGR 65.24% 6.66% 6.74%
Net income growth, 5-year CAGR 0.00% 14.08% 0.00%

Health

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
Debt to equity 0.90 0.19 0.05
Current ratio 2.31 1.90 2.31
Net debt to EBITDA (0.01) (0.15) 0.85

Dividend

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
Dividend yield — 0.66% 1.70%
Payout ratio 0.00 0.14 0.00

Size

Metric LQDA RDY Drug Manufacturers Specialty & Generic median
Market cap 6.36b 10.02b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack